Literature DB >> 32476836

Utility of precipitating antibody testing in the diagnostic evaluation of chronic hypersensitivity pneumonia.

Federica De Giacomi1, Anita Andreano2, Paola Faverio1, Alice Biffi1, Leonardo Ruvolo1, Nicola Sverzellati3, Maria Grazia Valsecchi2, Alberto Pesci1.   

Abstract

Background: Chronic hypersensitivity pneumonitis (HP), in its progressive fibrotic form, is difficult to distinguish from other fibrosing interstitial lung diseases (ILD), particularly idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP). The role of serum precipitating antibodies in the diagnosis of fibrosing ILD has not been discussed in recent clinical practice guidelines.
Objectives: The aim of this study is to assess the role of precipitins in the diagnosis of non pre-selected cases of fibrosing ILD.
Methods: Clinical records of 108 consecutive patients referred for presumptive fibrosing ILD to our institution were retrospectively assessed for exposure history, serum precipitins, other diagnostic examinations, and multidisciplinary diagnosis (MDD). Their high resolution computed tomography (HRCT) images were blindly and prospectively re-assessed. We estimated sensitivity and specificity of precipitins against MDD and, to account for incorporation bias, we used two composite reference standards (CRSs), having exposure history and HRCT as component tests.
Results: Definitive diagnosis achieved through MDD were chronic HP (17% of cases), NSIP (42%), IPF (18%) and others (23%). For serum precipitins, we estimated a sensitivity of 72% and a specificity of 68% using MDD as the reference standard. Sensitivity against the AND-CRS was 55%, while specificity against the OR-CRS was 61%. On the basis of this results, we can expect true sensitivity of precipitins lying between 55 and 72% and specificity between 61 and 68%. Conclusions:Serum precipitating antibodies did not result as having a relevant role in the diagnostic approach to chronic HP (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 149-155). Copyright:
© 2017.

Entities:  

Keywords:  hypersensitivity pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease; precipitins

Year:  2017        PMID: 32476836      PMCID: PMC7170133          DOI: 10.36141/svdld.v34i2.5467

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  26 in total

1.  Empirical evidence of design-related bias in studies of diagnostic tests.

Authors:  J G Lijmer; B W Mol; S Heisterkamp; G J Bonsel; M H Prins; J H van der Meulen; P M Bossuyt
Journal:  JAMA       Date:  1999-09-15       Impact factor: 56.272

2.  Diagnostic value of serum precipitins to mould antigens in active hypersensitivity pneumonitis.

Authors:  C-M Fenoglio; G Reboux; B Sudre; M Mercier; S Roussel; J-F Cordier; R Piarroux; J-C Dalphin
Journal:  Eur Respir J       Date:  2006-12-20       Impact factor: 16.671

3.  Chronic hypersensitivity pneumonitis.

Authors:  Andrew Churg; Nestor L Muller; Julia Flint; Joanne L Wright
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

4.  Pigeon fanciers' lung: effects of smoking on serum and salivary antibody responses to pigeon antigens.

Authors:  C I Baldwin; A Todd; S Bourke; A Allen; J E Calvert
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

5.  Exposure to microorganisms, airway inflammatory changes and immune reactions in asymptomatic dairy farmers. Bronchoalveolar lavage evidence of macrophage activation and permeability changes in the airways.

Authors:  K Larsson; P Malmberg; A Eklund; L Belin; E Blaschke
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

Review 6.  Needs and opportunities for research in hypersensitivity pneumonitis.

Authors:  Jordan N Fink; Hector G Ortega; Herbert Y Reynolds; Yvon F Cormier; Leland L Fan; Teri J Franks; Kathleen Kreiss; Steven Kunkel; David Lynch; Santiago Quirce; Cecile Rose; Robert P Schleimer; Mark R Schuyler; Moises Selman; Douglas Trout; Yasuyuki Yoshizawa
Journal:  Am J Respir Crit Care Med       Date:  2005-01-18       Impact factor: 21.405

7.  Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study.

Authors:  Ferran Morell; Ana Villar; María-Ángeles Montero; Xavier Muñoz; Thomas V Colby; Sudhakar Pipvath; María-Jesús Cruz; Ganesh Raghu
Journal:  Lancet Respir Med       Date:  2013-10-21       Impact factor: 30.700

8.  Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT.

Authors:  C Isabela S Silva; Nestor L Müller; David A Lynch; Douglas Curran-Everett; Kevin K Brown; Kyung Soo Lee; Man Pyo Chung; Andrew Churg
Journal:  Radiology       Date:  2008-01       Impact factor: 11.105

9.  HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation.

Authors:  Z A Aziz; A U Wells; D M Hansell; G A Bain; S J Copley; S R Desai; S M Ellis; F V Gleeson; S Grubnic; A G Nicholson; S P G Padley; K S Pointon; J H Reynolds; R J H Robertson; M B Rubens
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

10.  The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.

Authors:  Jason S Vourlekis; Marvin I Schwarz; Reuben M Cherniack; Douglas Curran-Everett; Carlyne D Cool; Rubin M Tuder; Talmadge E King; Kevin K Brown
Journal:  Am J Med       Date:  2004-05-15       Impact factor: 4.965

View more
  2 in total

1.  Cytokine gene polymorphisms in Pigeon Breeder's Disease expression.

Authors:  Cláudia Freitas; Bruno Lima; Natália Martins; Natália Melo; Patrícia Mota; Hélder Novais-Bastos; Helena Alves; Oksana Sokhatska; Luís Delgado; António Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-09-30       Impact factor: 0.670

2.  Predictive value of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with hypersensitivity pneumonia.

Authors:  Fatma Üçsular; Gülru Polat; Gülistan Karadeniz; Aysu Ayranci; Merve Keskin; Melih Buyukşirin; Filiz Güldaval; Enver Yalniz
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-12-16       Impact factor: 0.670

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.